ReviewCurrent neuropharmacology2023
Epilepsy and Cognitive Impairment in Childhood and Adolescence: A Mini-Review.
Review in Current neuropharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- A simulation training of family management for parents of children with epilepsy: a randomized clinical trial.Italian journal of pediatrics · 2024Trial
- The Mechanism of Long Non-coding RNA GABPB1-AS1/SLC12A5 Regulating Neuronal Ferroptosis in Epileptic Seizures.Neurochemical research · 2026Article
- Prevalence and factors associated with intellectual impairment in children with epilepsy in two national referral hospitals in Uganda.Acta epileptologica · 2026Article
- The Impact of Early-Life Seizures on the Maturation of Corticohippocampal Frequency Coordination.Journal of molecular neuroscience : MN · 2026Article
- The effect of physical activity on epileptic seizures and consequentlearning and memory impairment in electrical amygdala kindling model.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Memantine Confers Multi-Target Protection in a Zebrafish Seizure Model: Attenuating Epileptic Behavior, GluN2A Overexpression, and Oxidative Stress.Journal of neurochemistry · 2026Article
- Doxorubicin compromises blood-brain barrier integrity by suppressing annexin A1 expression.Open life sciences · 2026Article
- Case Report: Early surgical intervention for epilepsy with mild MOGHE: timing and clinical efficacy.Frontiers in pediatrics · 2026Article
- REST/NRSF Regulation of Epilepsy and Cognitive Impairment: Mechanisms and EEG Correlations.Molecular neurobiology · 2025Article
- EEG microstates, spectral analysis, and risk prediction in epilepsy comorbid with mild cognitive impairment: alteration in intrinsic brain activity.Journal of translational medicine · 2025Article
- Adult hippocampal neurogenesis: New avenues for treatment of brain disorders.Stem cell reports · 2025Review
- Cognitive Decline in Nasopharyngeal Carcinoma Survivors with Post-Radiation Epilepsy: A Prospective Cohort Study.Cancers · 2025Article
- Review
- Global first-in-class drugs approved in 2023-2024: Breakthroughs and insights.Innovation (Cambridge (Mass.)) · 2025Review
- Clinical characteristics, etiology, and treatment of young adult-onset epilepsy: A 24-year retrospective study.Epilepsia open · 2025Article
- Anti-GAD65 Antibodies Related Refractory Epilepsy Successfully Treated with Tocilizumab: A Case Report and Systematic Literature Review.ImmunoTargets and therapy · 2025Article
- Lactate Ameliorates Kainic Acid-Induced Neuroinflammation and Cognitive Impairment via the Chemokine Signaling Pathway in Mice.Journal of inflammation research · 2025Article
- Increase of Brivaracetam serum concentration with introduction of Cenobamate.Frontiers in pharmacology · 2025Article
- Decision-making impairments in epilepsy: behavioral and EEG evidence of event-related potential.Frontiers in neuroscience · 2025Article
- Correlation Between Liver Function and Risk of Post-Stroke Epilepsy.Journal of multidisciplinary healthcare · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Managing epilepsy in people with an intellectual disability remains a therapeutic challenge and must take into account additional issues such as diagnostic difficulties and frequent drug resistance. Advances in genomic technologies improved our understanding of epilepsy and raised the possibility to develop patients-tailored treatments acting on the key molecular mechanisms involved in the development of the disease. In addition to conventional antiseizure medications (ASMs), ketogenic diet, hormone therapy and epilepsy surgery play an important role, especially in cases of drugresistance. This review aims to provide a comprehensive overview of the mainfactors influencing cognition in children and adolescents with epilepsy and the main therapeutic options available for the epilepsies associated with intellectual disability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.